AGC to Acquire Malgrat Pharma Chemicals

AGC Inc. has entered into an agreement with Boehringer Ingelheim to acquire its subsidiary Malgrat Pharma Chemicals, S.L.U. (MPC). According to AGC, this acquisition will give the company its first FDA-registered site in Europe in the synthetic pharmaceutical contract development and manufacturing organization (CDMO) business. It will also enable AGC to cater its CDMO services to European customer requirements and expand its presence in that market, the company stated. The acquisition remains subject to approval from the relevant antitrust authorities and the fulfillment of closing conditions under the share purchase agreement.

The AGC Group stated that it will continue to actively invest in the life sciences field to provide globally unified high-quality services to customers in both the synthetic drug and biopharmaceutical businesses. The group added that it intends to maximize the synergies of each location to enhance its technical capabilities, making it possible to better contribute to pharmaceutical companies, patients, and wider society in general.